Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-001 in advanced head and neck cancers
NCT07072325Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Fc Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of CD-001 in head and neck cancer (HNC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse events up to 12 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
CD-001
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07072325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072325.